GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Market Cap

89bio (ETNB) Market Cap : $923.02 Mil (As of Dec. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is 89bio Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). 89bio's share price for the quarter that ended in Sep. 2024 was $7.4. 89bio's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 106.13 Mil. Therefore, 89bio's market cap for the quarter that ended in Sep. 2024 was $785.33 Mil.

89bio's quarterly market cap declined from Mar. 2024 ($1,108.12 Mil) to Jun. 2024 ($840.37 Mil) and declined from Jun. 2024 ($840.37 Mil) to Sep. 2024 ($785.33 Mil).

89bio's annual market cap increased from Dec. 2021 ($265.55 Mil) to Dec. 2022 ($643.64 Mil) and increased from Dec. 2022 ($643.64 Mil) to Dec. 2023 ($1,041.82 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. 89bio's Enterprise Value for Today is $559.16 Mil.


89bio Market Cap Historical Data

The historical data trend for 89bio's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Market Cap Chart

89bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial 362.51 485.74 265.55 643.64 1,041.82

89bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,167.86 1,041.82 1,108.12 840.37 785.33

Competitive Comparison of 89bio's Market Cap

For the Biotechnology subindustry, 89bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


89bio's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 89bio's Market Cap distribution charts can be found below:

* The bar in red indicates where 89bio's Market Cap falls into.



89bio Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

89bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$11.17*93.2694
=$1,041.82

89bio's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$7.4*106.126
=$785.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


89bio  (NAS:ETNB) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


89bio Market Cap Related Terms

Thank you for viewing the detailed overview of 89bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


89bio Business Description

Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
Rohan Palekar director, officer: Chief Executive Officer 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Quoc Le-nguyen officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen Laporte director
Atkinson Edward Morrow Iii director C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Ryan Martins officer: Chief Financial Officer 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg director, 10 percent owner 100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz director, 10 percent owner 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026